Comparison of a recombinant endotoxin-neutralizing protein with a human monoclonal antibody to endotoxin for the treatment of Escherichia coli sepsis in rats.

A recombinant endotoxin-neutralizing protein (ENP) from Limulus polyphemus and a monoclonal IgM anti-lipid A antibody (HA-1A) were compared in a rat model of Escherichia coli sepsis. One hour after intraperitoneal challenge with 10(6) cfu of E. coli O18ac K1, animals were sensitized to endotoxin with lead acetate and treated with ENP, HA-1A, or saline, followed by ceftriaxone and gentamicin. Before treatment, 95% of rats had high-grade bacteremia and high serum endotoxin concentrations, which were similar in all treatment groups (P > .60). One hour after treatment, there was no bacterial growth in any blood sample, and endotoxin concentrations were significantly lower in the ENP group than in the HA-1A and saline groups (P < .01). At 24 h after challenge, survival in the ENP group was significantly higher than in the HA-1A saline group (P < .001). ENP improved survival in a rat model of E. coli sepsis with high mortality despite effective antibiotic therapy.

[1]  B. Hammer,et al.  Effect of a recombinant endotoxin‐neutralizing protein on endotoxin shock in rabbits , 1994, Critical care medicine.

[2]  B. Hammer,et al.  Efficacy of a recombinant endotoxin neutralizing protein in rabbits with Escherichia coli sepsis. , 1994, Circulatory shock.

[3]  G. Mccracken,et al.  Sepsis syndrome and septic shock in pediatrics: current concepts of terminology, pathophysiology, and management. , 1993, The Journal of pediatrics.

[4]  J. Luce.  Introduction of new technology into critical care practice: A history of HA‐1A human monoclonal antibody against endotoxin , 1993, Critical care medicine.

[5]  J. Cohen,et al.  Purified monoclonal antibody to endotoxin core fails to protect mice from experimental gram-negative sepsis. , 1993, The Journal of infectious diseases.

[6]  D. Alling,et al.  A controlled trial of HA-1A in a canine model of gram-negative septic shock. , 1993, JAMA.

[7]  J. Cavaillon,et al.  Assessment of ability of murine and human anti-lipid A monoclonal antibodies to bind and neutralize lipopolysaccharide , 1993, The Journal of experimental medicine.

[8]  H. S. Warren,et al.  Binding and neutralization of endotoxin by Limulus antilipopolysaccharide factor , 1992, Infection and immunity.

[9]  C. Thompson,et al.  Limulus antilipopolysaccharide factor protects rabbits from meningococcal endotoxin shock. , 1992, Journal of Infectious Diseases.

[10]  R. Bone,et al.  The pathogenesis of sepsis. , 1991, Annals of internal medicine.

[11]  M. A. Martin,et al.  A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. The XOMA Sepsis Study Group. , 1991, JAMA.

[12]  C. McClain,et al.  Lead enhances lipopolysaccharide and tumor necrosis factor liver injury. , 1991, The Journal of laboratory and clinical medicine.

[13]  C. Sprung,et al.  Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group. , 1991 .

[14]  D. Dunn.  Development and potential use of antibody directed against lipopolysaccharide for the treatment of gram-negative bacterial sepsis. , 1990, The Journal of trauma.

[15]  W. Buurman,et al.  Monoclonal antibody to endotoxin core protects mice from Escherichia coli sepsis by a mechanism independent of tumor necrosis factor and interleukin-6. , 1990, The Journal of infectious diseases.

[16]  G. Grau,et al.  Association between protective efficacy of anti-lipopolysaccharide (LPS) antibodies and suppression of LPS-induced tumor necrosis factor alpha and interleukin 6. Comparison of O side chain-specific antibodies with core LPS antibodies , 1990, The Journal of experimental medicine.

[17]  L. Bermudez,et al.  Monoclonal antibodies for treatment of gram-negative infections. , 1989, Reviews of infectious diseases.

[18]  J. Harlan,et al.  Antilipopolysaccharide factor from horseshoe crab, Tachypleus tridentatus, inhibits lipopolysaccharide activation of cultured human endothelial cells , 1989, Infection and immunity.

[19]  T. Clemmer,et al.  A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. , 1987, The New England journal of medicine.

[20]  T. Miyata,et al.  Primary structure of limulus anticoagulant anti-lipopolysaccharide factor. , 1986, The Journal of biological chemistry.

[21]  H. Kaplan,et al.  Protection against gram-negative bacteremia and endotoxemia with human monoclonal IgM antibodies. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[22]  W. Reutter,et al.  Galactosamine-induced sensitization to the lethal effects of endotoxin. , 1979, Proceedings of the National Academy of Sciences of the United States of America.

[23]  J. Bartlett,et al.  Experimental Intra-Abdominal Abscesses in Rats: Development of an Experimental Model , 1974, Infection and immunity.

[24]  H. Selye,et al.  Effect of Lead Acetate on the Susceptibility of Rats to Bacterial Endotoxins , 1966, Journal of bacteriology.

[25]  J. Maessen,et al.  Role of tumour necrosis factor in the enhanced sensitivity of mice to endotoxin after exposure to lead. , 1989, Immunopharmacology and immunotoxicology.

[26]  S. Iwanaga,et al.  Primary structure of anti-lipopolysaccharide factor from American horseshoe crab, Limulus polyphemus. , 1987, Journal of Biochemistry (Tokyo).